
|Articles|February 15, 2003
Foresighted
Novartis Ophthalmics and Valley Forge Pharmaceuticals Inc. have entered into a licensing agreement for a novel eye medication for myopia, which in phase II clinical trials reduced progression of the disease by 50% in the first 12 months of therapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement

















